Second, in the treatment group, Bsep increased and Ntcp decreased, liver function damage was reduced, alanine aminotransferase and glutamic oxaloacetic aminotransferase were reduced, the bilirubin content was reduced, and the degree of cholestasis was improved. This evidence concerns the gene SLC10A1 and cholestasis.